371 related articles for article (PubMed ID: 33120755)
1. Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast: A case report.
Zhang Y; Liu C; Zheng C; Ren Q; Wang Q; Gao X; He Y; Wu J; Chen G; Li X; Ma Z
Medicine (Baltimore); 2020 Oct; 99(43):e22652. PubMed ID: 33120755
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy.
Liu X; Qu H; Cao W; Wang Y; Ma Z; Li F; Wang H
Endocr J; 2013; 60(6):819-28. PubMed ID: 23714650
[TBL] [Abstract][Full Text] [Related]
3. [A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M
Gan To Kagaku Ryoho; 2010 Jan; 37(1):111-3. PubMed ID: 20087042
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant endocrine therapy in breast cancer.
Beresford MJ; Ravichandran D; Makris A
Cancer Treat Rev; 2007 Feb; 33(1):48-57. PubMed ID: 17134840
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
Dellapasqua S; Gray KP; Munzone E; Rubino D; Gianni L; Johansson H; Viale G; Ribi K; Bernhard J; Kammler R; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Colleoni M;
J Clin Oncol; 2019 Feb; 37(5):386-395. PubMed ID: 30589600
[TBL] [Abstract][Full Text] [Related]
6. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
7. [A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].
Baba S; Oji Y; Teramoto M; Kawabata K; Saito A
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1905-6. PubMed ID: 19920398
[TBL] [Abstract][Full Text] [Related]
8. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant endocrine therapy for locally advanced breast cancer].
Viola G; Sergi D; Conti F; Lopez M
Clin Ter; 2007; 158(5):441-52. PubMed ID: 18062352
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy.
Zhu Y; Li Q; Gao J; He Z; Sun R; Shen G; Zhang H; Xia W; Xu J
Breast J; 2013; 19(4):382-7. PubMed ID: 23721399
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.
Ueno T; Masuda N; Kamigaki S; Morimoto T; Akiyama F; Kurosumi M; Tsuda H; Mikami Y; Tanaka S; Morita S; Toi M
Cancer Med; 2018 Jun; 7(6):2442-2451. PubMed ID: 29733541
[TBL] [Abstract][Full Text] [Related]
14. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
Gazet JC; Ford HT; Gray R; McConkey C; Sutcliffe R; Quilliam J; Makinde V; Lowndes S; Coombes RC
Ann Oncol; 2001 May; 12(5):685-91. PubMed ID: 11432629
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
18. Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study.
Wu S; Li Q; Zhu Y; Sun J; Li F; Lin H; Guan X; He Z
Cancer Biother Radiopharm; 2013 Dec; 28(10):697-702. PubMed ID: 23806020
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
Aihara T; Munakata S; Morino H; Takatsuka Y
J Surg Oncol; 2004 Feb; 85(2):77-81. PubMed ID: 14755507
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
